BIND Therapeutics, a clinical-stage biotech developing a platform of targeted and programmable therapeutics, announced terms for its IPO on Thursday. The Cambridge, MA-based company plans to raise $71 million by offering 4.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, BIND Therapeutics would command a market value of $237 million.
BIND Therapeutics, which was founded in 2006 and booked $5 million in sales for the 12 months ended June 30, 2013, plans to list on the NASDAQ under the symbol BIND. BIND Therapeutics initially filed confidentially on June 28, 2013. Credit Suisse and Cowen & Company are the joint bookrunners on the deal.
